サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1304526

固形腫瘍治療薬の世界市場-2023年～2030年

Global Solid Tumor Therapeutics Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
固形腫瘍治療薬の世界市場-2023年～2030年
出版日: 2023年07月07日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

固形腫瘍治療薬の世界市場は2022年に1,941億米ドルに達し、2030年には5億6,560万米ドルに達するなど、有利な成長が予測されています。固形腫瘍治療薬の世界市場は、2023～2030年の予測期間中に14.8%のCAGRを示すと予測されています。

個別化医療技術は、腫瘍の分子的・遺伝的側面においてより大きな可能性を秘めています。個々の患者の腫瘍プロファイルに基づいて、治療計画をより正確に的を絞って効果的に行うことができ、副作用を軽減して患者の転帰を改善することができます。固形腫瘍に対する革新的な治療法の発見と開発には、より多くの研究開発が必要です。

市場力学

固形腫瘍に対する先進的な治療法を開発するための主要企業間の協力関係の高まりが、予測期間中の世界の固形腫瘍治療薬市場の成長を後押ししています

2022年10月、細胞治療バイオテクノロジーのリーダーであるInceptor Bio社と細胞工学技術のパイオニアであるAvectas社は、固形腫瘍治療のための未来のCAR-T細胞治療の設計と生産を進めるための提携を発表しました。契約によると、Inceptor社はエレクトロポレーション法の代わりにAvectas社のSOLUPORE技術を使用して、より健康的なT細胞製品を生産するためにT細胞を工学的に作製します。

Inceptor Bio社が用いるCAR-T細胞のアプローチは、改変されたT細胞の質を向上させ、最終的に腫瘍微小環境における耐久性を高めることを目的としており、Avectas社のソルポアテクノロジーと相性が良いです。Inceptor Bio社のCAR-T細胞治療プラットフォームとAvectas社のソルポアデリバリーは、改変細胞の性能と有効性を高める可能性があります。

技術の進歩は、予測期間中の世界の固形腫瘍治療薬市場の成長を後押ししています

2022年10月、細胞治療バイオテクノロジーのリーダーであるInceptor Bio社と細胞工学技術のパイオニアであるAvectas社は、固形腫瘍治療のための未来のCAR-T細胞治療の設計と生産を進めるための提携を発表しました。

本契約によると、Inceptor社はエレクトロポレーション法の代わりにAvectas社のSOLUPORE技術を使用し、より健康的なT細胞製品を製造するためにT細胞を工学的に処理します。Inceptor Bio社が用いるCAR-T細胞のアプローチは、改変されたT細胞の質を向上させ、最終的に腫瘍微小環境における耐久性を高めることを目的としており、Avectas社のソルポアテクノロジーと相性が良いです。Inceptor Bio社のCAR-T細胞治療プラットフォームとAvectas社のソルポアデリバリーは、改変細胞の性能と有効性を高める可能性があります。

FDAの承認と調査活動は、世界の固形腫瘍治療薬市場に成長機会をもたらします

2022年6月、InvectysとCTMCのヒト白血球抗原A（HLA-G）標的キメラ抗原受容体（CAR）T細胞療法IVS-3001が固形腫瘍治療薬としてFDAの認可を受けた。INDクリアランスに続くヒト初となる非盲検単群フェーズ1/2a試験は、標準治療が無効または不耐容で、局所進行性、切除不能または転移性、組織学的または病理学的に確認されたHLA-G+固形腫瘍患者を対象に、本療法の安全性、忍容性、臨床活性、薬物動態を評価します。

COVID-19影響分析

COVID-19の流行は固形腫瘍治療薬市場に大きな影響を与えています。パンデミックは、がん検診や診断検査といった通常のヘルスケアサービスに影響を及ぼしています。その結果、固形腫瘍の診断とその後の治療開始が遅れています。診断の遅れは、治療実施時に病期が重篤化し、レジメンの有効性に影響を及ぼす可能性があります。

2023年現在、COVID-19の状況は回復しており、すべてのヘルスケア施設が患者にとって利用しやすくなっているため、固形腫瘍治療薬市場の需要は世界中で増加しています。

ロシア・ウクライナ紛争分析

ロシア・ウクライナ紛争が固形腫瘍治療薬市場に与える影響は複雑かつ多面的です。病院、診療所、その他の医療施設が破壊されたり、アクセス不能になったりしたため、患者はタイムリーで適切な治療や優れた腫瘍治療を受けることが困難になる可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • がん罹患率の増加
    • 抑制要因
      • 固形腫瘍治療薬に伴う副作用
    • 機会
      • 研究開発活動の活発化
    • 影響分析

第5章 産業分析

  • ポーターの5フォース分析
  • サプライチェーン分析
  • アンメットニーズ
  • 規制分析

第6章 COVID-19分析

第7章 ロシア・ウクライナ戦争分析

第8章 人工知能分析

第9章 がんタイプ別

  • 前立腺がん
  • 大腸がん
  • 肺がん
  • 乳がん
  • 子宮頸がん
  • その他

第10章 薬剤タイプ別

  • カルボプラチン
  • シスプラチン
  • ゲムシタビン
  • パクリタキセル
  • ドキソルビシン
  • ベバシズマブ
  • エルロチニブ
  • スニチニブ
  • エベロリムサ
  • その他

第11章 エンドユーザー別

  • 病院
  • 専門クリニック
  • 在宅医療
  • その他

第12章 流通チャネル別

  • 小売薬局
  • 病院薬局
  • オンライン薬局

第13章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第14章 競合情勢

  • 競合シナリオ
  • 製品ベンチマーク
  • 企業シェア分析
  • 主な発展と戦略

第15章 企業プロファイル

  • Sanofi
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Amgen Inc.
  • AstraZeneca PLC
  • Baxter International Inc.
  • Biogen Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC

第16章 付録

目次
Product Code: PH457

Market Overview

The Global Solid Tumor Therapeutics Market reached US$ 194.1 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 565.6 million by 2030. The Global Solid Tumor Therapeutics Market is expected to exhibit a CAGR of 14.8% during the forecast period 2023-2030.

Personalized medicine techniques have more potential in tumors' molecular and genetic aspects. Based on the tumor profiles of individual patients, treatment plans can be more precisely targeted and effective, reducing side effects and improving patient outcomes. To find and develop innovative therapies for solid tumors more research and development is required.

Market Dynamics

The growing collaboration among key players to develop advanced treatments for solid tumors is boosting the global solid tumor therapeutics market growth during the forecast period.

In October 2022, Inceptor Bio, a leader in cell therapy biotechnology, and Avectas, a pioneer in cell engineering technology, announced their partnership to advance the design and production of CAR-T cell treatments of the future for the treatment of solid tumors. According to the agreement, Inceptor will use Avectas' SOLUPORE technology instead of electroporation to engineer T cells to produce a healthier T cell product.

The CAR-T cell approach used by Inceptor Bio, which aims to improve the quality of the modified T cells and ultimately increase their endurance in the tumor microenvironment, is well matched to Avectas' SOLUPORE technology. The CAR-T cell treatment platform from Inceptor Bio and Avectas' SOLUPORE delivery could enhance the performance and efficacy of the modified cells.

Technological advancements are boosting the global solid tumor therapeutics market growth during the forecast period.

In October 2022, Inceptor Bio, a leader in cell therapy biotechnology, and Avectas, a pioneer in cell engineering technology, announce their partnership to advance the design and production of CAR-T cell treatments of the future for the treatment of solid tumors.

According to the agreement, Inceptor will use Avectas' SOLUPORE technology instead of electroporation to engineer T cells to produce a healthier T cell product. The CAR-T cell approach used by Inceptor Bio, which aims to improve the quality of the modified T cells and ultimately increase their endurance in the tumor microenvironment, is well matched to Avectas' SOLUPORE technology. The CAR-T cell treatment platform from Inceptor Bio and Avectas' SOLUPORE delivery could enhance the performance and efficacy of the modified cells.

FDA approval and research activities provide solid tumor therapeutics global solid tumor therapeutics market growth opportunities.

In June 2022, the human leukocyte antigen A (HLA-G) targeting chimeric antigen receptor (CAR) T-cell therapy IVS-3001 from Invectys and CTMC received FDA clearance for the treatment of solid tumors. Following IND clearance. The first-in-human, open-label, single-arm phase 1/2a study will assess the therapy's safety, tolerability, clinical activity, and pharmacokinetics in patients with HLA-G + solid tumors that have failed or been intolerant to standard-of-care therapies and are locally advanced, unresectable, or metastatic and have been confirmed by histology or pathology.

COVID-19 Impact Analysis

The COVID-19 pandemic has significantly impacted the solid tumor therapeutics market. The pandemic has affected regular healthcare services, such as cancer screenings and diagnostic tests. As a result, the diagnosis of solid tumors and the start of subsequent therapy have been delayed. Delayed diagnosis might lead to more severe disease stages when therapy is administered, affecting the regimen's effectiveness.

As of 2023, the COVID-19 situation is recovering and all healthcare facilities are accessible to patients leading to increasing demand for the solid tumor therapeutics market worldwide.

Russia-Ukraine Conflict Analysis

The impact of the Russia-Ukraine war on the solid tumor therapeutics market is complex and multifaceted In the impacted areas, the violence has caused the destruction and interruption of the healthcare infrastructure. Patients may have difficulty receiving timely and adequate treatment and excellent tumor therapies because hospitals, clinics, and other medical facilities may have been destroyed or rendered inaccessible.

Segment Analysis

The Global Solid Tumor Therapeutics Market is segmented based on cancer type, drug type, end-user, distribution channel, and region.

The breast cancer segment is expected to hold a dominant position in the market over the forecast period.

The breast cancer segment accounted for the highest market stake, accounting for approximately 27.6% of the solid tumor therapeutics market in 2022. According to a study published in an NCBI article in 2022, the tumor is removed, which causes discomfort or difficulties to go away.

Breast cancer is the most prevalent cancer among women, accounting for more than 1 in 10 new cancer diagnoses yearly. It is the second most frequent cancer-related death among women worldwide. Breast cancer develops slowly, and most cases are found through routine screenings.

Geographical Analysis

The increasing prevalence of cancer, increasing FDA approvals, and advancement in solid tumor therapeutics dominate the North American region.

North America is expected to dominate the solid tumor therapeutics market, accounting for around 40.8%. Lung cancer is diagnosed in the United States every two and a half minutes, and it claims the lives of more than 356 of our friends, neighbors, and loved ones every day. However, there is optimism now because more Americans are surviving lung cancer than ever before.

The survival rate has grown by 21% nationally to 25% over the previous five years. Still, it has remained much lower among communities of color, at 20%, even though the disease remains the top cause of cancer deaths. This year's report also looks at the relevance of advances in lung cancer research, which offer better treatment options, and the potentially life-saving potential of lung cancer screening, which can identify the disease at an earlier stage when it's more treatable.

Competitive Landscape

The major global players in the market include: Sanofi, Amgen Inc., AstraZeneca PLC, Baxter International Inc., Biogen Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, and GlaxoSmithKline PLC among others.

Why Purchase the Report?

  • To visualize the Global Solid Tumor Therapeutics Market segmentation based on the cancer type, drug type, end-user, distribution channel, and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous solid tumor therapeutics market-level data points with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The Global Solid Tumor Therapeutics Market Report Would Provide Approximately 69 Tables, 78 Figures And 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Cancer Type
  • 3.2. Snippet by Drug Type
  • 3.3. Snippet by End-user
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Incidence of cancer
    • 4.1.2. Restraints
      • 4.1.2.1. Side effects associated with solid tumor therapeutics
    • 4.1.3. Opportunity
      • 4.1.3.1. Rising research and development activities
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Analysis

9. By Cancer Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 9.1.2. Market Attractiveness Index, By Cancer Type
  • 9.2. Prostate Cancer*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Colorectal Cancer
  • 9.4. Lung Cancer
  • 9.5. Breast Cancer
  • 9.6. Cervical Cancer
  • 9.7. Others

10. By Drug Type

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.1.2. Market Attractiveness Index, By Drug Type
  • 10.2. Carboplatin*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Cisplatin
  • 10.4. Gemcitabine
  • 10.5. Paclitaxel
  • 10.6. Doxorubicin
  • 10.7. Bevacizumab
  • 10.8. Erlotinib
  • 10.9. Sunitinib
  • 10.10. Everolimusa
  • 10.11. Others

11. By End-user

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 11.1.2. Market Attractiveness Index, By End-user
  • 11.2. Hospitals*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Specialty Clinics
  • 11.4. Homecare
  • 11.5. Others

12. By Distribution Channel

    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.1.2. Market Attractiveness Index, By Distribution Channel
  • 12.2. Retail Pharmacies*
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 12.3. Hospital Pharmacies
  • 12.4. Online Pharmacies

13. By Region

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 13.1.2. Market Attractiveness Index, By Region
  • 13.2. North America
    • 13.2.1. Introduction
    • 13.2.2. Key Region-Specific Dynamics
    • 13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.2.7.1. The U.S.
      • 13.2.7.2. Canada
      • 13.2.7.3. Mexico
  • 13.3. Europe
    • 13.3.1. Introduction
    • 13.3.2. Key Region-Specific Dynamics
    • 13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.3.7.1. Germany
      • 13.3.7.2. The U.K.
      • 13.3.7.3. France
      • 13.3.7.4. Italy
      • 13.3.7.5. Spain
      • 13.3.7.6. Rest of Europe
  • 13.4. South America
    • 13.4.1. Introduction
    • 13.4.2. Key Region-Specific Dynamics
    • 13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.4.7.1. Brazil
      • 13.4.7.2. Argentina
      • 13.4.7.3. Rest of South America
  • 13.5. Asia-Pacific
    • 13.5.1. Introduction
    • 13.5.2. Key Region-Specific Dynamics
    • 13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.5.7.1. China
      • 13.5.7.2. India
      • 13.5.7.3. Japan
      • 13.5.7.4. Australia
      • 13.5.7.5. Rest of Asia-Pacific
  • 13.6. Middle East and Africa
    • 13.6.1. Introduction
    • 13.6.2. Key Region-Specific Dynamics
    • 13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

14. Competitive Landscape

  • 14.1. Competitive Scenario
  • 14.2. Product Benchmarking
  • 14.3. Company Share Analysis
  • 14.4. Key Developments and Strategies

15. Company Profiles

  • 15.1. Sanofi*
    • 15.1.1. Company Overview
    • 15.1.2. Product Portfolio and Description
    • 15.1.3. Financial Overview
    • 15.1.4. Key Developments
  • 15.2. Amgen Inc.
  • 15.3. AstraZeneca PLC
  • 15.4. Baxter International Inc.
  • 15.5. Biogen Inc.
  • 15.6. Boehringer Ingelheim GmbH
  • 15.7. Bristol-Myers Squibb Company
  • 15.8. Eli Lilly and Company
  • 15.9. F. Hoffmann-La Roche AG
  • 15.10. GlaxoSmithKline PLC

LIST NOT EXHAUSTIVE

16. Appendix

  • 16.1. About Us and Services
  • 16.2. Contact Us